Stock Movers: NatWest Surges, GSK Dips, Accor Gains on Guidance

NatWest's Strong Earnings Performance

• 📈 NatWest shares soared to a 15-year high following strong third-quarter results that beat estimates.
• 💰 The bank reported a 30% increase in pre-tax profit compared to the previous year, marking its highest earnings in at least a decade.
• 🏦 This performance is attributed to benefiting from higher interest rates and the CEO's focus on becoming a simpler bank with tight cost control and digital transformation.
• 📊 The results, alongside retail data, suggest that UK customers are coping well with economic headwinds.

GSK's Blood Cancer Drug Approval and Concerns

• 🔬 US regulators approved GSK's blood cancer drug, Blendre, allowing its re-entry into the market after being pulled in 2022.
• ⚠️ Despite the approval, GSK shares dropped due to caveats accompanying the approval, including a smaller-than-expected eligibility pool and concerns about the drug's sales potential.
• 📉 These concerns about the commercial viability are dragging down the stock price, impacting the FTSE 100.

Accor's Positive Outlook and Buyback

• 🏨 Accor shares gained following an increase in the hotelier's guidance, driven by improved cost discipline and portfolio simplification.
• 💸 The company announced a new €100 million share buyback for the fourth quarter.
• 🚀 Accor also confirmed plans to potentially list its lifestyle brands portfolio, contributing to a positive trajectory for its stock.
• 🌍 While commenting positively on current trading, the company noted potential weaknesses in markets like Germany and China.